Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Nicotine 8.3mg (10cm² patch delivers 5mg/16hours.);
Johnson & Johnson (New Zealand) Limited
Nicotine 8.3 mg (10cm² patch delivers 5mg/16hours.)
5mg/16hours
Transdermal patch
Active: Nicotine 8.3mg (10cm² patch delivers 5mg/16hours.)
Individual wrap, 7x10cm� patches, 7 patches
General sale
General sale
Siegfried Ltd
Package - Contents - Shelf Life: Individual wrap, 7x10cm? patches - 7 patches - 36 months from date of manufacture stored at or below 25°C
1991-06-28
Medsafe Logo INFORMATION FOR CONSUMERS Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search Consumer Medicine Information NICORETTE ® Patch Nicotine 5 mg/16h, 10 mg/16h, 15 mg/16h, transdermal patch What is in this leaflet This leaflet answers some common questions about Nicorette Patch. It does not contain all the available information or take the place of professional advice such as talking to your doctor or pharmacist. All medicines have risks and benefits. You need to weigh the risks of using Nicorette Patch against the benefits it will have for you. If you have any concerns about using this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What Nicorette Patch is used for Nicorette Patch helps you to give up smoking by relieving the desire to smoke, as well as some of the unpleasant effects, which smokers experience when they stop smoking. How Nicorette Patch works Smokers have both a physical reliance on nicotine (i.e. the body becomes dependent on nicotine) and a psychological reliance on the smoking habit itself. When you give up smoking, your body will miss the effects of nicotine and you will miss the habit of smoking. Nicorette Patch helps you to tackle these two sides of the problem separately, instead of all at once. It is your body's dependence on nicotine, which causes withdrawal symptoms when you suddenly stop smoking. Nicotine is an addictive substance. Symptoms may include irritability, restlessness, depression, weight gain, and craving for cigarettes. weight gain, and craving for cigarettes. Nicorette Patch is intended to ease such withdrawal symptoms by providing your body with nicotine. This leaves your mind free to concentrate o Read the complete document
HOME | CONSUMERS | HEALTH PROFESSIONALS | REGULATORY | OTHER | HOT TOPICS | SEARCH DATA SHEET NICORETTE ® PATCH 5MG/16H, 10MG/16H, 15MG/16H PRESENTATION Nicorette Patch is a transdermal delivery system for topical application, available in sizes of 30, 20 and 10 cm 2 each containing 0.83 mg/cm 2 of nicotine, releasing 15 mg, 10 mg and 5 mg respectively over 16 hours. Each patch is rectangular in shape and comprises 3 distinct layers; an outer beige matt finish backing layer, a patterned silvery middle layer and an inner clear release liner, which is removed prior to use. Each patch is packaged in a heat sealed multilaminate sachet. USES ACTIONS Pharmacotherapeutic group: Drug for treatment of addiction. ATC code: N07B A01 Abrupt cessation of the use of tobacco-containing products following a prolonged period of daily use results in a characteristic withdrawal syndrome that includes four or more of the following: dysphoria or depressed mood; insomnia; irritability, frustration or anger; anxiety; difficulty concentrating, restlessness or impatience; decreased heart rate; and increased appetite or weight gain. Nicotine craving, which is recognised as a clinically relevant symptom, is also an important element in nicotine withdrawal. Clinical studies have shown that nicotine replacement products can help smokers abstain from smoking. PHARMACOKINETICS GENERAL PHARMACOKINETIC PROPERTIES OF NICOTINE The volume of distribution following i.v. administration of nicotine is about 2 to 3 L/kg. Plasma protein binding of nicotine is <5%. Therefore, changes in nicotine binding from use of concomitant drugs or alterations of plasma proteins by disease states would not be expected to have significant effects on nicotine kinetics. The average plasma clearance following intravenous administration of nicotine is about 70 L/hour and the terminal half-life approximately 2 hours. The major eliminat Read the complete document